Novavax, Inc. (NVV1.F)
EUR 8.74
(0.66%)
EUR 8.74
(0.66%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 212.61 Million USD | -69.47% |
| 2022 | 696.31 Million USD | -39.26% |
| 2021 | 1.14 Billion USD | 141.02% |
| 2020 | 475.59 Million USD | 2448.48% |
| 2019 | 18.66 Million USD | -45.57% |
| 2018 | 34.28 Million USD | 9.98% |
| 2017 | 31.17 Million USD | 114.01% |
| 2016 | -222.58 Million USD | -76.1% |
| 2015 | -126.39 Million USD | -906.5% |
| 2014 | 15.67 Million USD | 23.47% |
| 2013 | 12.69 Million USD | 71.9% |
| 2012 | 7.38 Million USD | -3.92% |
| 2011 | 7.68 Million USD | 2140.52% |
| 2010 | 343 Thousand USD | 5.54% |
| 2009 | 325 Thousand USD | -69.45% |
| 2008 | 1.06 Million USD | -17.65% |
| 2007 | 1.29 Million USD | 172.18% |
| 2006 | -1.79 Million USD | -212.09% |
| 2005 | 1.59 Million USD | -66.52% |
| 2004 | 4.77 Million USD | -50.97% |
| 2003 | 9.72 Million USD | -15.01% |
| 2002 | 11.44 Million USD | -42.81% |
| 2001 | 20.01 Million USD | 552.13% |
| 2000 | 3.06 Million USD | 91.81% |
| 1999 | 1.6 Million USD | 60.0% |
| 1998 | 1 Million USD | 25.0% |
| 1997 | 800 Thousand USD | 100.0% |
| 1996 | 400 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 369.24 Million USD | 965.76% |
| 2024 Q1 | 34.64 Million USD | -64.8% |
| 2023 Q4 | 98.42 Million USD | 228.05% |
| 2023 Q3 | -76.86 Million USD | -120.85% |
| 2023 Q2 | 368.64 Million USD | 1009.93% |
| 2023 Q1 | -40.51 Million USD | -138.2% |
| 2023 FY | 212.61 Million USD | -69.47% |
| 2022 Q3 | 299.98 Million USD | 452.29% |
| 2022 FY | 696.31 Million USD | -39.26% |
| 2022 Q1 | 688.76 Million USD | 209.98% |
| 2022 Q2 | -85.15 Million USD | -112.36% |
| 2022 Q4 | 106.06 Million USD | -64.64% |
| 2021 Q1 | 447.22 Million USD | 59.92% |
| 2021 Q3 | 178.84 Million USD | -39.99% |
| 2021 Q2 | 298.01 Million USD | -33.36% |
| 2021 FY | 1.14 Billion USD | 141.02% |
| 2021 Q4 | 222.2 Million USD | 24.24% |
| 2020 FY | 475.59 Million USD | 2448.48% |
| 2020 Q2 | 35.53 Million USD | 952.35% |
| 2020 Q3 | 157.02 Million USD | 341.85% |
| 2020 Q4 | 279.65 Million USD | 78.1% |
| 2020 Q1 | 3.37 Million USD | -61.69% |
| 2019 Q2 | 3.35 Million USD | -15.7% |
| 2019 FY | 18.66 Million USD | -45.57% |
| 2019 Q4 | 8.81 Million USD | 251.66% |
| 2019 Q1 | 3.98 Million USD | -35.01% |
| 2019 Q3 | 2.5 Million USD | -25.32% |
| 2018 FY | 34.28 Million USD | 9.98% |
| 2018 Q4 | 6.12 Million USD | -20.79% |
| 2018 Q3 | 7.73 Million USD | -28.2% |
| 2018 Q2 | 10.77 Million USD | 11.6% |
| 2018 Q1 | 9.65 Million USD | -7.29% |
| 2017 Q4 | 10.41 Million USD | 24.66% |
| 2017 Q1 | 5.68 Million USD | 5.2% |
| 2017 FY | 31.17 Million USD | 114.01% |
| 2017 Q2 | 6.73 Million USD | 18.52% |
| 2017 Q3 | 8.35 Million USD | 24.06% |
| 2016 FY | -222.58 Million USD | -76.1% |
| 2016 Q3 | 3.23 Million USD | 28.98% |
| 2016 Q2 | 2.5 Million USD | -40.61% |
| 2016 Q4 | 5.39 Million USD | 67.1% |
| 2016 Q1 | 4.21 Million USD | -27.93% |
| 2015 Q2 | 11.3 Million USD | 52.45% |
| 2015 FY | -126.39 Million USD | -906.5% |
| 2015 Q4 | 5.85 Million USD | 54.92% |
| 2015 Q1 | 7.41 Million USD | 90.84% |
| 2015 Q3 | 3.77 Million USD | -66.59% |
| 2014 Q2 | 3.15 Million USD | -28.91% |
| 2014 Q3 | 4.18 Million USD | 32.63% |
| 2014 FY | 15.67 Million USD | 23.47% |
| 2014 Q4 | 3.88 Million USD | -7.17% |
| 2014 Q1 | 4.44 Million USD | -27.73% |
| 2013 Q3 | 2.52 Million USD | 33.02% |
| 2013 FY | 12.69 Million USD | 71.9% |
| 2013 Q2 | 1.89 Million USD | -10.47% |
| 2013 Q1 | 2.12 Million USD | -18.86% |
| 2013 Q4 | 6.14 Million USD | 143.27% |
| 2012 FY | 7.38 Million USD | -3.92% |
| 2012 Q4 | 2.61 Million USD | 35.65% |
| 2012 Q2 | 1.98 Million USD | 131.89% |
| 2012 Q1 | 856 Thousand USD | 173.92% |
| 2012 Q3 | 1.92 Million USD | -2.92% |
| 2011 Q1 | 834 Thousand USD | 1535.29% |
| 2011 FY | 7.68 Million USD | 2140.52% |
| 2011 Q4 | -1.15 Million USD | -123.12% |
| 2011 Q3 | 5 Million USD | 66.88% |
| 2011 Q2 | 3 Million USD | 259.83% |
| 2010 Q3 | 175 Thousand USD | 2400.0% |
| 2010 Q2 | 7000.00 USD | -93.64% |
| 2010 Q4 | 51 Thousand USD | -70.86% |
| 2010 Q1 | 110 Thousand USD | 48.65% |
| 2010 FY | 343 Thousand USD | 5.54% |
| 2009 Q2 | 29 Thousand USD | 38.1% |
| 2009 Q1 | 21 Thousand USD | -70.0% |
| 2009 FY | 325 Thousand USD | -69.45% |
| 2009 Q4 | 74 Thousand USD | -63.18% |
| 2009 Q3 | 201 Thousand USD | 593.1% |
| 2008 Q2 | 342 Thousand USD | -25.33% |
| 2008 Q1 | 458 Thousand USD | -81.07% |
| 2008 FY | 1.06 Million USD | -17.65% |
| 2008 Q3 | 194 Thousand USD | -43.27% |
| 2008 Q4 | 70 Thousand USD | -63.92% |
| 2007 Q4 | 2.41 Million USD | 1004.57% |
| 2007 Q3 | 219 Thousand USD | 131.42% |
| 2007 Q2 | -697 Thousand USD | 5.3% |
| 2007 Q1 | -736 Thousand USD | 52.85% |
| 2007 FY | 1.29 Million USD | 172.18% |
| 2006 Q1 | -245 Thousand USD | -116.04% |
| 2006 Q4 | -1.56 Million USD | -6886.96% |
| 2006 FY | -1.79 Million USD | -212.09% |
| 2006 Q3 | 23 Thousand USD | 107.14% |
| 2006 Q2 | -322 Thousand USD | -31.43% |
| 2005 Q4 | 1.52 Million USD | 91.11% |
| 2005 FY | 1.59 Million USD | -66.52% |
| 2005 Q3 | 799 Thousand USD | 177.43% |
| 2005 Q2 | 288 Thousand USD | 128.32% |
| 2005 Q1 | -1.01 Million USD | -248.68% |
| 2004 Q4 | 684 Thousand USD | 136.68% |
| 2004 Q1 | 2.95 Million USD | -12.39% |
| 2004 FY | 4.77 Million USD | -50.97% |
| 2004 Q3 | 289 Thousand USD | -80.78% |
| 2004 Q2 | 1.5 Million USD | -49.14% |
| 2003 Q3 | 3.5 Million USD | 85.9% |
| 2003 FY | 9.72 Million USD | -15.01% |
| 2003 Q1 | 960 Thousand USD | -0.83% |
| 2003 Q2 | 1.88 Million USD | 96.56% |
| 2003 Q4 | 3.37 Million USD | -3.79% |
| 2002 Q3 | 1.7 Million USD | -54.38% |
| 2002 Q2 | 3.73 Million USD | -25.81% |
| 2002 Q4 | 968 Thousand USD | -43.23% |
| 2002 Q1 | 5.03 Million USD | 0.92% |
| 2002 FY | 11.44 Million USD | -42.81% |
| 2001 Q2 | 6.88 Million USD | 75.48% |
| 2001 Q1 | 3.92 Million USD | 259.25% |
| 2001 Q3 | 4.21 Million USD | -38.76% |
| 2001 FY | 20.01 Million USD | 552.13% |
| 2001 Q4 | 4.99 Million USD | 18.38% |
| 2000 Q2 | 692 Thousand USD | -14.78% |
| 2000 Q3 | 473 Thousand USD | -31.65% |
| 2000 Q4 | 1.09 Million USD | 130.87% |
| 2000 FY | 3.06 Million USD | 91.81% |
| 2000 Q1 | 812 Thousand USD | 1.5% |
| 1999 Q2 | 300 Thousand USD | 50.0% |
| 1999 Q4 | 800 Thousand USD | 166.67% |
| 1999 Q3 | 300 Thousand USD | 0.0% |
| 1999 Q1 | 200 Thousand USD | -33.33% |
| 1999 FY | 1.6 Million USD | 60.0% |
| 1998 Q2 | 200 Thousand USD | -33.33% |
| 1998 Q3 | 200 Thousand USD | 0.0% |
| 1998 Q4 | 300 Thousand USD | 50.0% |
| 1998 FY | 1 Million USD | 25.0% |
| 1998 Q1 | 300 Thousand USD | -25.0% |
| 1997 Q2 | 100 Thousand USD | -50.0% |
| 1997 Q3 | 200 Thousand USD | 100.0% |
| 1997 FY | 800 Thousand USD | 100.0% |
| 1997 Q4 | 400 Thousand USD | 100.0% |
| 1997 Q1 | 200 Thousand USD | 100.0% |
| 1996 Q3 | 200 Thousand USD | 0.0% |
| 1996 Q1 | 200 Thousand USD | 0.0% |
| 1996 Q4 | 100 Thousand USD | -50.0% |
| 1996 Q2 | 200 Thousand USD | 0.0% |
| 1996 FY | 400 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioNTech SE | 3.21 Billion EUR | 93.395% |
| CureVac N.V. | -70.6 Million EUR | 401.119% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 21.804% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 21.804% |
| BRAIN Biotech AG | 30.12 Million EUR | -605.843% |
| Formycon AG | 23.3 Million EUR | -812.311% |
| Heidelberg Pharma AG | 6.6 Million EUR | -3118.457% |
| Medigene AG | 4.39 Million EUR | -4742.041% |